Edwards Q3 Earnings & Revenues Surpass Estimates, Stock Climbs

Impact · against what's priced in

Edwards Lifesciences delivered a beat on both top and bottom lines, driven by a 44% surge in TMTT sales and steady TAVR growth. While the results are positive, the modest operational margin expansion suggests that profitability gains are largely driven by currency tails rather than structural efficiency.

EW+0.50

No priced-in read yet

In context

Q3 adjusted EPS of 80 cents and revenue of $1.72 billion both beat consensus, supported by strong TMTT growth of 44% and an 8% increase in core TAVR sales.

Read from the article alone

• EW▲400%
• earnings▲2%
• healthcare
• revenue
• eps
• medical devices
• tavr

Top 2 movers · tap to explore